TY - BOOK PY - 2017 DA - 2017// TI - Hepatitis B Fact Sheet PB - WHO CY - Geneva ID - ref1 ER - TY - STD TI - Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden disease study 2013. Lancet 2016;388:1081–1088. ID - ref2 ER - TY - BOOK PY - 2016 DA - 2016// TI - Global Health Sector Strategy on Viral Hepatitis. Towards Ending Viral Hepatitis PB - WHO CY - Geneva ID - ref3 ER - TY - STD TI - Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521–1531. ID - ref4 ER - TY - STD TI - Kim WR, Loomba R, Berg T, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 2015;121:3631–3638. ID - ref5 ER - TY - STD TI - Marcellin P, Gane E, Buti M. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468–475. ID - ref6 ER - TY - STD TI - European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167–185. ID - ref7 ER - TY - BOOK PY - 2017 DA - 2017// TI - Global Hepatitis Report, 2017 PB - WHO CY - Geneva ID - ref8 ER - TY - STD TI - Lemoine M, Shimakawa Y, Njie R, et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. Lancet Glob Health 2016;4:e559–e567. ID - ref9 ER - TY - STD TI - Belyhun Y, Maier M, Mulu A, Diro E, Liebert UG. Hepatitis viruses in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis 2016;16:761. ID - ref10 ER - TY - STD TI - Chon YE, Choi EH, Song KJ, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One 2012;7:e44930. ID - ref11 ER - TY - STD TI - Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut 2016;65:1369–1376. ID - ref12 ER - TY - BOOK PY - 2015 DA - 2015// TI - Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection PB - WHO CY - Geneva ID - ref13 ER - TY - STD TI - Sangeda RZ, Mosha F, Prosperi M, et al. Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health 2014;14:1035. ID - ref14 ER - TY - STD TI - Boursier J, Konate A, Gorea G, et al. Reproducibility of liver stiffness measurement by ultrasonographic elastometry. Clin Gastroenterol Hepatol 2008;6:1263–1269. ID - ref15 ER - TY - STD TI - Marcellin P, Heathcote J, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. JAMA 2008;359:2442–2455. ID - ref16 ER - TY - STD TI - von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453–1457. ID - ref17 ER - TY - STD TI - Sanne I, Orrell C, Fox MP, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomized non-inferiority trial. Lancet 2010;376:33–40. ID - ref18 ER - TY - STD TI - Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176–182. ID - ref19 ER - TY - STD TI - Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J Viral Hepat 2012;19:377–386. ID - ref20 ER - TY - STD TI - Goyal SK, Dixit VK, Shukla SK, et al. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis. Indian J Gastroenterol 2015;34:286–291. ID - ref21 ER - TY - STD TI - Hou JL, Jia JD, Wei L, et al. Efficacy and safety of entecavir in a heterogenous CHB population from a ‘real-world’ clinical practice setting in China. J Viral Hepat 2013;20:811–820. ID - ref22 ER - TY - STD TI - Petersen J, Heyne R, Mauss S, et al. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year prospective field practice study in Germany. Dig Dis Sci 2016;61:3061–3071. ID - ref23 ER - TY - STD TI - Ha NB, Ha NB, Garcia RT, et al. Medication nonadherence with long-term management of patients with hepatitis B e-antigen negative chronic hepatitis B. Dig Dis Sci 2011;56:2423–2431. ID - ref24 ER - TY - STD TI - Sogni P, Carrieri MP, Fontaine H, et al. The role of adherence in virological suppression in patients receiving anti-HBV analogues. Antivir Ther 2012;17:395–400. ID - ref25 ER - TY - STD TI - Liu Y, Corsa AC, Buti M, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat 2017;24:68–74. ID - ref26 ER - TY - STD TI - Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006;296:679–690. ID - ref27 ER - TY - STD TI - Desalegn H, Aberra H, Berhe N, Gundersen SG, Johannessen A. Are non-invasive fibrosis markers for chronic hepatitis B valid in sub-Saharan Africa? Liver Int 2017;37:1461–1467. ID - ref28 ER - TY - STD TI - Afdhal NH, Bacon BR, Patel K, et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicentre study. Clin Gastroenterol Hepatol 2015;13:772–779. ID - ref29 ER - TY - STD TI - Stene-Johansen K, Yaqoob N, Øverbø J, et al. Dried blood spots a reliable method for measurement of HBV viral load in resource-limited settings. PLoS One 2016;11:e0166201. ID - ref30 ER -